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Abstract
Background: Despite evidence supporting the preventative potential of HIV Treatment as Prevention (TasP),
scientific experts and community stakeholders have suggested that the success of TasP at the population level will
require overcoming a set of complex and population-specific implementation challenges. For example, the factors
that might influence decisions to initiate ‘early’ treatment have yet to be thoroughly understood; neither have
questions about the factors that enhance or impede their ability to achieve long-term adherence to ARVs or the
social norms regarding various treatment regimens been examined in detail. This knowledge gap may hamper
opportunities to effectively develop public health practices that are informed by the various challenges and
opportunities related to TasP implementation and scale up.
Methods: Drawing on 50 in-depth, individual interviews with young men ages 18–24 in Vancouver, Canada, this
study examines young men’s perspectives regarding factors that might affect their engagement with TasP.
Results: While findings from the current study indicate young men generally have a high receptiveness to TasP,
our findings also identify key social and structural forces that will warrant ongoing consideration for TasP implementation.
For example, participants described how an enhanced awareness regarding treatment (including awareness of the
universal availability of treatment in Vancouver) would be a necessary, but not sufficient, condition to decide to endorse
TasP. Their decisions about engaging in HIV care in the context of TasP (e.g., HIV testing, treatment initiation, long-term
adherence) also appear to be contingent on their ability to negotiate or ‘balance’ the risks and benefits to themselves and
others. The findings also offer insight into the complex and sometimes controversial narratives that continue to emerge
regarding risk compensation practices in the context of TasP.
Conclusion: Based on the results of this study, we identify several areas that hold promise for informing the effective
scale up of TasP, including new information regarding implementation adaptation strategies.
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Background
A growing number of clinical trials, cohort studies and
mathematical modeling analyses indicate that antiretro-
viral (ARV) treatment is effective in reducing the on-
ward transmission of HIV from seropositive to
seronegative individuals [1–5]. As a result, regional and
global HIV prevention efforts are increasingly relying
upon HIV Treatment as Prevention (TasP) approaches
as a key component of broader efforts to address the
HIV epidemic, as evidenced by the UNAIDS’ [6] recent
adoption of the ‘90-90-90’ testing, treatment and viral
load suppression targets. Despite evidence supporting
the preventative potential of TasP, scientific experts and
community stakeholders have suggested that the success
of TasP at the population level will require overcoming a
set of complex and population-specific implementation
challenges.
Treatment as prevention
The role of TasP within the rapidly transforming ARV-
based prevention arena has had a significant impact in
re-shaping the broader HIV continuum of care. Today,
TasP is being implemented as a means to reduce sexual-
and injection-related transmission of HIV among a var-
iety of populations. Within the evidence in this area, a
landmark clinical trial-HPTN 052-indicated that ‘early’
initiation of ARVs can reduce the transmission of the
HIV virus among heterosexual serodiscordant couples
by up to 96 % compared to couples who initiate therapy
at previously recommended World Health Organization
thresholds (CD4 count < 250 cells/mm3) [5]. More re-
cently, the PARTNER Study (an investigation of HIV
transmission through vaginal and anal condomless sex
between serodiscordant heterosexual and MSM part-
ners) reported that, among couples initiating ARV treat-
ment, none had transmitted the virus to their partners
[7]. Given these promising clinical and epidemiological
findings, treatment is now widely accepted as having
both individual and community health benefits in that it
can prevent both HIV-related morbidity (e.g., progres-
sion to AIDS), as well as the onward transmission of
HIV infection [8, 9].
‘Fast-tracking’ the response to HIV/AIDS with TasP
In 2014 the UNAIDS called for a global scale-up of TasP
and efforts to meet the following ‘90-90-90’ targets by
2020: (1) 90 % of all people living with HIV will know
their HIV status; (2) 90 % of all people diagnosed with
HIV infection will receive antiretroviral therapy (ART),
that includes the use of ARVs; and (3) 90 % of all people
receiving ART will achieve viral suppression. These
commitments established a set of highly ambitious tar-
gets regarding the scale-up of TasP that, as indicated in
the ‘90-90-90’ target guidelines, require various global
and local settings to ‘tailor approaches to address the
unique challenges in diverse settings and populations’
[6].
Since 2010, Vancouver’s regional health authority has
implemented a voluntary routine offer model for HIV
testing in primary and acute care settings, aiming to in-
crease HIV testing rates by embedding testing within
routine care. Funding and policy commitments have also
supported universal availability of ARVs for HIV-positive
individuals, ‘earlier’ initiation of ARVs (i.e., as soon as
possible following seroconversion and regardless of an
individual’s CD4 count), and enhanced efforts to treat all
clinically eligible HIV-positive persons [10]. As such,
Vancouver provides an interesting implementation con-
text within which to examine factors that can influence
the scalability of TasP among a variety of key-affected
populations.
Young men and HIV care
Scaling up TasP programmes and service delivery prac-
tices may present a particularly salient set of implemen-
tation issues among young men-a group with high and
rising rates of HIV in addition to disproportionately low
levels of engagement with health care seeking behaviour
generally and HIV care specifically (e.g., compared to
older men and/or women). In 2012, for example, HIV
incidence rates for men between the ages of 20–24 and
25–29 in BC were significantly higher than the provin-
cial average at 7.7 and 22.0 cases per 100,000 (compared
to the provincial average of 5.2 per 100,000) [11]. More-
over, new HIV diagnoses in Vancouver have been in-
creasing among younger cohorts of MSM (born 1980–
1999), as compared with decreasing numbers of new
HIV diagnoses among MSM cohorts born pre-1980 [12].
As a result, HIV transmission in BC has been described
as a ‘re-emerging epidemic’ among young men, particu-
larly in marginalized subgroups of men including MSM
and men who inject drugs [12].
Previous work has shown how socio-cultural influ-
ences affect young men’s (non) participation in HIV test-
ing [13–16], particularly through social norms regarding
masculinity, stigma and wait times [15, 17]. Young men
also face challenges when accessing sexual health ser-
vices, including barriers to effective communication with
health professionals, that can be exacerbated through
enactments of hegemonic masculinity [13, 14, 18–20].
Furthermore, theories of gender relations, masculinities
and men’s health behaviour suggest that men’s health ex-
periences are influenced by the wider set of social rela-
tions [21–24] that vary across other aspects of the social
hierarchy (e.g., socio-economic status). In general, men
are less likely than women to seek care from health care
professionals and more likely to engage in medium- to
long-term self-treatment strategies, as well as position
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‘help-seeking’ behaviour as potentially emasculating [22,
23, 25, 26].
While there is a growing empirical and theoretical lit-
erature related to young men’s health-related practices
regarding their (non)participation with HIV testing, far
less is known about how young men perceive other
levels of the HIV continuum of care, particularly in the
rapidly evolving context of TasP. Previous research into
various levels of the HIV cascade of care, however, have
been extremely helpful at identifying how structural in-
fluences, including HIV stigma, can have vast implica-
tions for particular experiences with the HIV cascade of
care that hold relevance for the imperatives of TasP (e.g.,
barriers and facilitators to: HIV testing patterns; risk-
reduction practices; capacity for long-term adherence to
ART) [27]. With respect to TasP, a recent review [28] of
empirical literature investigating the acceptability of
ARV-based prevention strategies (specifically, TasP and
Pre-Exposure Prophylaxis-PrEP) found that only three of
33 relevant articles focused on TasP. Furthermore,
among the three TasP-related articles [29–31], none fo-
cused on the needs or perceptions of young men
specifically.
There is currently a dearth of information related to
how young men might respond to or perceive the evolv-
ing HIV continuum of care in the context of TasP and
given the universal availability of treatment in some set-
tings, including what TasP means for evolving ‘risk land-
scapes’ and testing practices of young men who are at
risk of contracting HIV, as well as those who may not be
aware of their serostatus. Moreover, the factors that
might influence young men’s decisions to initiate ‘early’
treatment have yet to be thoroughly understood; neither
have questions about the factors that enhance or impede
their ability to achieve long-term adherence to ARVs or
the social norms regarding various treatment regimens
been examined in detail. To date, these and other issues,
including young men’s perspectives on other potential
unanticipated consequences that may arise in the con-
text of TasP (e.g., risk compensation practices, such as
reduced rates of sustained condom and/or sterile syringe
use), remain largely unknown. This knowledge gap may
hamper opportunities to effectively develop public health
practices that are informed by the various challenges
and opportunities related to TasP implementation and
scale up among young men who are at risk for HIV and/
or may not be aware of their serostatus.
Purpose
The purpose of this study is to examine the knowledge,
attitudes and normative understandings of young men
who are at risk for HIV acquisition, including those who
may not be aware of their serostatus, regarding the test-
ing, treatment and long-term suppression imperatives of
TasP. To do so, we draw on data gathered through semi-
structured, in-depth individual interviews with 50 young
men (ages 18–24) in Vancouver, Canada.
Methods
For the reader, it is helpful to consider our motivations
for conducting this analysis. The current analysis was
conducted as a part of a larger program of research
identifying the structural and socio-cultural determi-
nants of young men’s sexual health, with particular at-
tention on the ethical and implementation factors
associated with Vancouver’s evolving HIV intervention
‘landscape’. Our analysis is grounded within a critical
realist perspective [32, 33] that hypothesizes that socio-
structural features of implementation context are dia-
lectically interrelated with both the outcomes of an
intervention (in this case, TasP) and the experiences of
the intervention ‘targets’ (in this case, both young men
who do and do not know their serostatus, and/or are at
risk of HIV). For example, we aim to identify how fea-
tures of contemporary socio-cultural contexts (e.g.,
norms about young people’s sexual health practices) in-
fluence young men’s perspectives and experiences re-
garding the testing, treatment and prevention
imperatives of TasP.
Recruitment and data collection
Data were collected between June and November 2013
in Vancouver, British Columbia (BC) in Canada, which
provides an ideal setting to examine perspectives about
TasP. We drew on a stratified purposeful approach to
sampling in order to capture variation within and across
various sub-groups of young men (e.g., various lived ex-
periences; social identities; behavioural, social and struc-
tural HIV risk profiles). In total, fifty young men ages
18–24 were recruited to participate in the study through
advertisements at clinical sites (e.g., posters at youth sex-
ual health clinics) and non-clinical settings (e.g., youth
centers; bus stops), as well as online (e.g., Facebook ad-
vertisements; Craigslist). Participants also were recruited
from the At-Risk Youth Study (ARYS), a prospective co-
hort of Vancouver youth who are or have previously
been street-involved and used illicit drugs (other than
marijuana) (see Wood et al. [34] for more information
on the ARYS cohort). Eligibility criteria include: ages
18–24; ability to speak and understand English; identify
as a man (including cisgender and/or trans* identified
men); currently sexually active or have been sexually ac-
tive previously.
Participants completed an informed consent form and
a 9-item socio-demographic questionnaire, prior to par-
ticipating in an in-depth, semi-structured, individual
interview (see Table 1 for additional information on the
questions and probes used during our interviews to
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discuss some of the tenets of TasP). All interviews were
audio-recorded and were conducted within our team re-
search offices. Participants were offered the choice to be
interviewed by a male interviewer (co-author RK) or a
female interviewer (a research assistant), though none
expressed a preference. Interviews lasted 1 to 1.5 h in
duration and were conducted by interviewers with train-
ing in qualitative health research methods, as well as ex-
tensive experience conducting interviews with young
men regarding sexual health. Participants were asked to
describe their thoughts regarding HIV treatment (e.g.,
availability; effectiveness) in Vancouver (and elsewhere).
They also were asked to describe their perceptions re-
garding the effectiveness of HIV treatment in terms of
the prognoses for HIV-positive individuals as well as
their opinions regarding the capacity of TasP to protect
seronegative partners (e.g., partners with whom they
share drugs; sex partners). Participants were provided
with a description of TasP and asked to describe the ex-
tent to which they felt these approaches were ‘fair’ and
‘justifiable’. Participants also were asked to explain
whether or not they perceived TasP to be something
they might consider for themselves (i.e., would they
choose to initiate treatment in the event of an HIV posi-
tive diagnosis for either or both treatment and preven-
tion reasons?).
We did not ask participants to disclose their HIV sta-
tus, a decision we arrived at only after considerable dis-
cussion and debate within our team. In the end, we
chose not to ask interview participants to disclose their
status for the following reasons. Firstly, the legal system
in Canada currently adopts a “criminalization” approach.
A 2012 ruling by the Supreme Court of Canada has
upheld the criminalization of HIV non-disclosure except
where both a condom is used and the person has a ‘low’
HIV viral load. A conviction of aggravated sexual assault
could result if these requirements are not followed.
Bearing all this in mind, we thought that it was not
warranted from an ethical perspective to ask study
participants to disclose their serostatus to us. Instead,
we have provided context regarding various aspects of
HIV-related risk at the individual level (e.g., use of
condoms; injection drug use) as well as at the structural
level (e.g., recent experiences with being street-entrenched
or homeless).
Participants received a CDN$25 honorarium to com-
pensate them for their participation. Ethics approval was
obtained from the University of British Columbia’s Be-
havioural Research Ethics Board (#H12-01936).
Data analysis
Interviews were transcribed and accuracy checked and
then uploaded to Nvivo10. First, co-authors RK and KT
read and re-read the transcripts, assigning initial codes
that were then grouped thematically. Next, we used an
open-coding approach in which coding was first orga-
nized into ‘trees’ to group the codes thematically. The
emergent thematic codes focused on capturing the mi-
cro- (e.g., previous experiences), meso- (e.g., interper-
sonal relations) and macro (e.g., socio-cultural) factors
that shape men’s opinions and behaviour related to HIV,
with a specific focus on ARV treatment initiation and
long-term adherence (e.g., successes, challenges). Dis-
crepancies between codes and coders were resolved
through discussion and re-visiting the raw data at coding
during team meetings. Next, each thematic was explored
further by asking three key analytic questions: (a) How
do men perceive HIV care in Vancouver in the context
of universally available treatment, and how might this
influence their engagement with TasP programmes and
service delivery practices?; (b) What are the factors that
influence men’s perceptions regarding HIV treatment
and TasP?; and (c) What do participants raise as import-
ant challenges or opportunities for young men’s engage-
ment with TasP? Thus, as we conducted our thematic
analysis, we employed both inductive and deductive ap-
proaches by continually comparing our emergent themes
Table 1 Questions and probes to specifically discuss TasP during the interviews
Questions Probes
Some people have told us that because there are more advanced
HIV treatment opportunities, some of the concerns related to HIV are
no longer as important.
a. What do you know about HIV treatment?
b. Providing treatment to people who are HIV+ can also make them
less infectious-in other words, if somebody who is HIV+ is receiving
treatment, they will not be as likely to give HIV to someone else.
This has been referred to as ‘treatment as prevention’, because the
treatment is offered to patients to prevent HIV transmission, regardless
of whether or not the individual is at a stage of HIV infection that
requires treatment for their individual benefit (e.g., so they don’t
become sick). What are your thoughts on offering treatment to
individuals who are HIV+ in order to prevent them from transmitting HIV?
• Tell me how the availability of HIV treatment might influence your decision
to go for HIV testing? How might the availability of treatment affect the
testing decisions of your friends (guys/girls)?
• How acceptable do you think it would be if you were HIV+ and you
were offered treatment so that you would not be infectious, rather
than for your own health-related concerns?
• Some have argued that it might be unfair to treat an HIV-infected person
in order to prevent them from infecting others because it places another
demand on people who might be very vulnerable people (e.g., poor people;
people who use injection drugs). Can you tell me what your thoughts are
on the ‘fairness’ of this approach?
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A total of 50 young men completed interviews. Partici-
pants ranged in age from 18 to 24 (mean age: 21.7).
Thirty-two percent (n = 16) of participants identified as
gay, bisexual or Two-Spirit, 68 % (n = 34) as straight.
Forty-eight percent (n = 24) were recruited from the
ARYS cohort, with the remaining 52 % (n = 26) recruited
either through online advertising or posters. Table 2
provides additional socio-demographic information of
our sample.
Overview of findings
We report our findings using two thematic categories
regarding the participants’ perceptions of TasP: (1) Re-
flections about treatment and treatment initiation in the
context of TasP; and (2) Perceived challenges and oppor-
tunities regarding long-term viral load suppression.
Quotations from participants’ transcripts are presented
to illustrate the various themes that arose during our in-
terviews and related to each thematic. Each quotation is
preceded by a short description of each participant’s
socio-demographic profile and a researcher-assigned nu-
meric code follows each quote.
Reflections about treatment and treatment initiation in
the context of TasP
Our interviews began by asking participants to describe
how their understandings of contemporary HIV treat-
ment regimens might influence their engagement with
HIV care. Within this conversation, some participants
explained that they had limited knowledge regarding
HIV treatment and asked our interviewers for some add-
itional information. We explained to the participants
that, when effectively treated and diagnosed early, HIV
seropositive individuals can expect a near normal quality
of life and longevity. Upon reflecting on this informa-
tion, several participants indicated that knowing more
about the availability and effectiveness of HIV treatment
might make them more likely to access HIV testing ser-
vices. For example, a 24-year-old straight man described:
I think knowing what it would be like if I tested
positive would make me more prone to get tested,
‘cause, like, I don’t know how justified this is, but I had
this idea that the prognosis is pretty bad. Maybe that’s
just ignorance, I don’t know. But I think if people knew
what happens next more, it would make testing more
easy to decide to do. (#020)
After reflecting on how available and highly effective HIV
treatment might influence their HIV testing practices, sev-
eral participants expressed concern that, despite the effect-
iveness of treatment, there would likely be ‘insurmountable’
economic barriers to acquiring treatment that they would
not be able to overcome – and these concerns were par-
ticularly salient among men experiencing multiple and
intersecting forms of disadvantage (e.g., living on the
streets; addiction issues). For example, after being informed
that treatment can greatly improve an HIV seropositive in-
dividual’s quality and length of life, a 22-year-old bisexual
man and a 20-year-old straight man expressed concern:
But I don’t know if that [information about HIV
treatment and prognoses] makes me any less
concerned about certain aspects of the disease just
because I also know that it’s [treatment] expensive,
and that definitely plays into me, ‘cause I know that if
I needed to afford expensive medication, I just couldn’t
right now. (#018)






South East Asian 7 14
Middle Eastern 1 2
Other 7 14
Living arrangement
With parents 9 18
With friends or partner 22 44
Alone 7 14
In a shelter or on the street 11 22







Transgender man 1 2
Cisgender man 49 98
Recruitment mechanism
Online advertising 23 46
Posters 2 4
ARYS study (see recruitment details
for information on the ARYS study)
24 48
Other 1 2
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You’re still fucked [in the event of an HIV diagnosis]. I
don’t even know if it’s covered by MSP [Medical
Services Plan, the provincial health care plan in the
province of British Columbia]. I highly doubt it. So if
you’re on welfare and you have HIV, I think you’re
pretty fucking screwed. And I would not want to have
to figure it out, either. (#041)
During this part of our interviews, we explained that
HIV treatment is universally available free-of-charge
through the medical services plan in BC to clinically eli-
gible patients. We also described to participants that
there are preventative benefits associated with HIV
treatment by explaining that HIV seropositive individuals
who achieve viral suppression are less likely to transmit
HIV to their uninfected partners. Upon reflecting on this
information, most participants were eager to learn more
about a variety of aspects of HIV treatment. For ex-
ample, when we asked them to consider the different
pieces of information that they would need to know in
order to inform their decision about treatment initiation,
the majority of participants described that they would
want to learn more about the various potential side
effects associated with HIV treatment. For instance, a
23-year-old straight participant explained how his
decision-making about treatment initiation would re-
quire a careful balance of the health benefits versus the
potential side effects associated with drug toxicity:
Participant: It [initiating ARVs] all depends on the
side effects of the treatment. If the side effects were
really serious, I probably would not want to do it,
because side effects from drugs, from treatment like
that, could be very serious. So, yeah, I probably would
not do it if the side effects were too serious.
Interviewer: Okay. And, if the side effects weren’t too
bad?
Participant: I would be very glad to do it so I don’t
spread it to other people. (#028)
At this point in our interviews, we provided partici-
pants with some additional information regarding HIV
treatment, including a description of how treatment is
now generally considered to be safe if treatment regimes
are effectively followed. As participants reflected on HIV
treatment and whether they might consider initiating
treatment, two dominant themes emerged from their
narratives about why they would consider initiating
treatment immediately following an HIV diagnosis. First,
participants described how preventing future harm (i.e.,
transmitting HIV) to their sex partners would represent
an important consideration. For example, one 22-year-
old bisexual participant described:
Personally, I’d go on that sort of treatment just to
make sure that it is safe for my partners. (#018)
The preventative benefits of treatment were also posi-
tioned as constituting a “public safety” measure in the par-
ticipants’ narratives about HIV treatment. For example,
another 22-year-old bisexual participant described:
If the medicine is destructive on the body then there
are certain compromises that can’t be made. But from
a point of public safety, I think it is important for
somebody to take it if they’re gonna be putting
themselves at risk of spreading it. (#007)
Similarly, among a small sub-set of participants, some
elaborated how treatment would also be a beneficial
means to protect the partners with whom they exchange
or share injection drug equipment. For example, a 24-
year-old straight man who had previously injected drugs
described how he would expect others who seroconvert
and inject drugs to initiate treatment in order to help
prevent the likelihood of onward transmission through
contaminated equipment:
I couldn’t imagine being like, “No, I don’t want to
go through treatment,” and just, like then being
completely sloppish about disposing of anything
with blood on it or like needles. I just don’t know
why someone would want to run the risk of infecting
someone. Like, why wouldn’t you want to get
treatment and just try to nip it in the bud as quick
as you can? (#031)
We also asked them to consider how they would want
to be offered treatment in the event of an HIV diagnosis.
Some of the participants expressed concern that clinical
communication strategies would need to be tailored in a
way that transparently delineates the various risks and
benefits associated with ‘early’ treatment initiation. For
example, one 23-year-old straight man explained:
I think if it’s [clinical recommendations regarding
ARV initiation] sort of proposed in the form of a
question or as a sort of an option amongst several,
right? Then I think those sorts of things continue to
respect the autonomy of other people. Whereas if it’s
kind of, you know, strongly recommended or, you know,
bordering on coercive, then I would question the
legitimacy of that kind of approach. (#013)
Some participants described how seropositive individ-
uals could feel ‘targeted’ within clinical encounters if
they perceived that their clinician was emphasizing
public health benefits (e.g., prevention of onward
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transmission) over clinical concern for the individual
patient being recommended for treatment. For ex-
ample, one participant described:
The person may feel like, ‘Well, you’re only making me
undergo treatment because you just wanna protect
those around me and decrease their chance of
contracting the infection, as opposed to treating me
and being concerned about me.’ So I can see the
person viewing the measure as ‘all but me.’ (#001)
Thus, within our interviews regarding treatment initi-
ation, participants’ responses underscored how their de-
cision making regarding the initiation of treatment in
the context of TasP would be contingent on their ability
to negotiate or ‘balance’ the risks and benefits to others
(e.g., preventing transmission of the virus) with the risks
and benefits to themselves (e.g., potential side effects of
treatment vs. personal ‘peace of mind’). Taken as a
whole, these narratives reveal that, despite having limited
awareness regarding TasP (e.g., the preventative capacity
of treatment; understandings about the universal avail-
ability of treatment in the Vancouver setting), participants
generally responded with high levels of acceptability and
receptiveness towards the approach.
Perceived challenges and opportunities regarding
long-term viral load suppression
We asked participants to reflect on the various chal-
lenges that young men who choose to initiate treat-
ment might face with regards to achieving long-term
adherence to treatment (and therefore be more likely
to achieve viral load suppression). Participants de-
scribed an array of different challenges, including how
various social and structural conditions could serve to
either positively or negatively impact young men’s
capacity to adhere to a treatment regimen. For in-
stance, a 20-year-old gay man described how the
places where one lives, and their socio-economic sta-
tus, would differentially influence one’s prospects for
successful adherence and health outcomes in the
event of an HIV diagnosis:
Even within Vancouver, I know that like if I’m a
homeless person with intravenous drug use on the
Downtown Eastside [an inner-city neighbourhood]
and I’m not eating right because I’m homeless and I
don’t have a job and I’ve been mentally ill, life is
going to be hard [in the event of an HIV diagnosis].
Whereas, if I’m a gay man on Davie Street [Vancou-
ver’s ‘gay village’] with a nice middle-class job, life is
going to be liveable. So I think even within Vancouver
there’s like, it depends on a lot, you know, your place
in society. (#014)
A sub-set of participants who had reported a history
of being street-entrenched also described how the vari-
ous hardships that they experience in ‘street life’ would
influence their capacity to adhere to treatment. For ex-
ample, a 24-year-old straight man and a 19-year-old
straight man who both were living on the street at the
time of our interview described how the challenges of
drug use and street life would likely influence adherence
rates:
I would think if you’re sharing rigs and out having
multiple partners and all that […] I can’t imagine
someone keeping up with the upkeep of doing that kind
of treatment or something, you know? […] That’s just, I
can’t see them having too much of a structure in their
life where they would have a daily routine to do
something like that. (#031)
Because, like, some people won’t take their pill. They
might be high, they might be sleeping, they might just
forget about it. (#040)
As the interviews progressed, some participants
expressed concern that individuals who choose to initi-
ate treatment might reduce their use of other HIV pre-
vention strategies. For example, a 23-year-old straight
man described how he worried condom use would de-
crease among those who choose to initiate ARVs:
Condom use would definitely go down without a
doubt, just because people would be, I think people
would contract HIV […] Like, “I can’t give somebody
HIV now, so there’s no need to use a condom”. Unless
they can still get them pregnant or something like that.
So, I think it would go down, and I don’t think that’s a
good thing. (#029)
Some participants described how ongoing public
health efforts might be able to mitigate these con-
cerns. For example, one 23-year-old bisexual partici-
pant described how a set of tailored clinical
communication strategies should be developed to in-
form men that TasP is not 100 % effective at pre-
venting HIV transmission:
I think it’s [TasP] good. But I think that, with it,
there should be a statement that says to people
that you’re not completely risk free. You are not
100 % risk free. […] I think there should be like,
at least fail-proof prevention that comes with the
medication to say that it would help protect
yourself and other people, but also, however, you
are not 100 % risk free so always advise your
partner that you’re HIV positive. (#038)
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While most participants tended to position TasP as
having an added benefit to individual HIV prevention
repertoires (e.g., how young men engage with testing,
treatment and prevention practices), one 20-year-old gay
participant expressed frustration that, as an HIV sero-
negative individual, he perceived that TasP puts the re-
sponsibility of HIV prevention largely in the hands of
seropositive individuals, as he described:
As a prevention strategy, I’m like, okay, that’s focusing
on the people who have HIV and could transmit it
which makes sense, I guess? But as it’s like me
personally as someone who would be getting the HIV,
it doesn’t do anything for me. […] Maybe that’s just
me being really self-interested in that I don’t see myself
as a gay men represented there-as an HIV negative
gay man. […] Yeah, cause it’s not ‘prevention as
prevention’, it’s ‘treatment as prevention’. But it takes
two people to transmit HIV, right? And [TasP is] only
dealing with half those people. (#014)
These findings begin to reveal how some men may
ascribe complex social meanings to TasP, where it might
simultaneously be perceived as over-emphasizing per-
sonal responsibility, while also being linked with risk
compensation practices that have negative connotations
in terms of social responsibility.
Discussion
Overall, knowledge levels regarding ARV treatment and
TasP were low. Most participants suggested that in-
creased awareness regarding ARV treatment (including
awareness of the universal availability of treatment in
the Vancouver setting) would be a necessary, but not a
sufficient condition to inform their decision-making re-
garding the use of ARVs for prevention or treatment. In-
stead, these decisions would more likely be contingent
on their ability to negotiate or ‘balance’ the risks and
benefits to themselves and others (e.g., preventing trans-
mission of the virus; potential side effects of ARVs; per-
sonal desires to know one’s HIV status). The current
study reveals how decisions to initiate TasP may be
strongly influenced by both the ability to keep one’s self
healthy, as well as the ability to protect others from in-
fection. Furthermore, the findings offer insight into the
complex and sometimes controversial narratives that
continue to emerge regarding risk compensation prac-
tices in the context of TasP [36, 37]. This remains an
area that requires more investigation to fully inform eth-
ical approaches to implementing and scaling up TasP in
ways that do not exacerbate ‘victim blaming’ [38].
The findings also highlight how the successful imple-
mentation of TasP will require a sophisticated set of
clinical communication strategies-even in settings where
ARVs are available universally-thereby underscoring the
extent to which TasP educational and communication ef-
forts should not be based solely at ‘target’ populations
(e.g., young men), but also to those tasked with imple-
menting TasP at the patient-clinician interface [39]. For
example, clinicians require the resources and skill sets to
provide knowledge that patients require to make in-
formed decisions regarding TasP-including the side ef-
fects associated with initiating ARVs and their capacity
to reduce onward disease transmission. Excellent com-
munication strategies are particularly salient given that
new evidence regarding the risks and benefits of ‘early’
initiation of treatment (i.e., immediately following sero-
conversion) is rapidly unfolding. Rapidly changing infor-
mation ‘landscapes’ pose significant challenges to clinical
discussions and demand a high level of commitment to
staying current and remaining open to change as new
evidence emerges regarding best clinical practice. For
example, while some have expressed concern that early
initiation of ARVs may lead to an increase in potential
side effects, including reduced bone density and kidney
damage as well as the potential for an individual’s
virus to develop resistance to ARVs [40], emerging
evidence indicates the individual benefits (e.g., de-
creased incidence of primary and secondary infec-
tions) associated with early uptake may outweigh the
negative side effects [41, 42].
We were also struck by the concerns expressed by sev-
eral participants that TasP strategies could tend to disre-
gard the interests of HIV-negative individuals by not
affording them enhanced agency or opportunity to en-
gage in individual risk-reduction practices. While at first
these concerns seemed to contradict the acknowledge-
ment that TasP can have community-wide benefits by
reducing the incidence of HIV, it is worth reflecting,
however, the extent to which these concerns are es-
poused from within a socio-historical context in which
public health has largely placed the responsibility of HIV
prevention at the level of the individual, rather than via
broad, structural and population-level interventions. In-
deed, the young men in this study recognized the pre-
ventative capacity of TasP, while not privileging it as the
only way to prevent HIV transmission or acquisition. In
doing so, these narratives tended to align more closely
with the messaging within contemporary cascades of
care that emphasize combination approaches to HIV risk
reduction.
Sampling (e.g., due to under-coverage, some popula-
tion sub-groups of young men may not be adequately
represented) and participation bias (e.g., men who
choose to volunteer for a study about HIV may tend to
have a similar set of experiences or beliefs about HIV)
may have influenced the sample composition and do not
fully reflect all variations of young men’s perspectives
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regarding TasP. As such, the findings are not claimed as
‘representative’ or generalizable to all young men. More-
over, the potential amplification of response biases (e.g.,
social desirability bias) may have also influenced the
sorts of responses participants felt appropriate in the
context of an interview about young men’s sexual health.
While, towards the end of our data collection activities
(i.e., after the 40th interview), new insights were no lon-
ger generated regarding TasP (thereby indicating theor-
etical saturation was attained), the findings are not
claimed as ‘representative’ or generalizable to all young
men. Nonetheless, our study provides rich insights into
the perspectives of a diverse group of young men within
Vancouver (including those from population sub-groups
of men who have historically been characterized as being
‘high risk’ for HIV acquisition), thereby revealing a set of
implementation challenges and opportunities for scaling
up TasP programs and service delivery practices in this
setting.
Conclusion
Overall, these findings provide important opportunities
for those charged with implementing and scaling up
TasP efforts, including achieving the 90-90-90 testing,
treatment and adherence targets. Clinicians and public
health campaigners alike may benefit from better under-
standings of key target populations’ perspectives regarding
TasP (e.g., perceptions about the availability of treatment;
their perspectives on treatment initiation and long-term
adherence). While findings from the current study indi-
cate young men generally have a high receptiveness to
TasP, our findings also identify key social and structural
forces that will warrant ongoing consideration for TasP
implementation.
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